Mithra Pharmaceuticals S.A. (MITPF) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Mithra Pharmaceuticals S.A. (MITPF) trades at $23.90 with AI Score 43/100 (Grade C). Mithra Pharmaceuticals S. A. Market cap: $1.60B, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Jun 15, 2026Analyst Coverage for MITPF: MITPF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates MITPF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
MITPF: 2/3 scored disciplines lean bearish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Mithra Pharmaceuticals S.A. (MITPF) Healthcare & Pipeline Overview
Mithra Pharmaceuticals S.A. is a Belgian pharmaceutical firm focused on women's health, developing and manufacturing advanced therapeutic solutions for contraception, menopause management, and hormone-dependent cancers. The company leverages a pipeline of estetrol-based products, including late-stage candidates like Estelle and Donesta, positioning itself within a specialized and evolving market segment.
What Is the Investment Thesis for MITPF?
Mithra Pharmaceuticals S.A. is positioned within the specialized women's health sector, focusing on high-demand areas like contraception and menopause management. The company's valuation, represented by a $1.60B market capitalization, reflects its ongoing development efforts rather than current profitability, as evidenced by a significant profit margin of -432.1%. A key value driver is its advanced product pipeline, particularly Estelle and Donesta, both in late-stage clinical development. Successful regulatory approvals and commercialization of these estetrol-based products could significantly enhance revenue streams and market penetration. The company's gross margin of 14.9% indicates some efficiency in production, but overall profitability remains challenged by R&D expenses inherent in pharmaceutical development. The low Beta of 0.60 suggests relatively lower volatility compared to the broader market. Future growth is contingent on successful clinical trial outcomes, regulatory clearances, and effective market launches, especially for its innovative hormonal therapies, which address substantial global health needs.
Based on FMP financials and quantitative analysis
MITPF Key Highlights
Market capitalization of $1.60B reflects the company's current valuation in the market, primarily driven by its development pipeline.
- Profit margin of -432.1% indicates significant net losses, typical for a pharmaceutical company heavily investing in research and development prior to widespread commercialization.
- Gross margin of 14.9% demonstrates the company's ability to generate revenue above the direct costs of goods sold, even amidst overall unprofitability.
- A Beta of 0.60 suggests Mithra Pharmaceuticals S.A. stock has historically exhibited lower volatility compared to the overall market.
- The ongoing Phase III development of Donesta, an estetrol-based oral hormone treatment, represents a critical near-term milestone for potential market entry and revenue generation.
Who Are MITPF's Competitors?
MITPF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| NPNKF Nippon Shinyaku Co., Ltd. | $23.50 | +0.00% | $1.58B | 61 |
| ANIP ANI Pharmaceuticals, Inc. | $77.32 | -0.90% | $1.76B | 95 |
| ALVO Alvotech | $4.27 | +7.02% | $1.44B | 69 |
| PAHC Phibro Animal Health Corporation | $35.18 | -0.73% | $1.43B | 76 |
| CASBF CanSino Biologics Inc. | $3.90 | +24.01% | $1.36B | 63 |
| AVDL Avadel Pharmaceuticals plc | $21.64 | +0.00% | $2.12B | 64 |
| CRON Cronos Group Inc. | $3.22 | -2.13% | $1.20B | 62 |
| DCPH Deciphera Pharmaceuticals | $25.59 | +0.08% | $2.21B | 61 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are MITPF's Key Strengths?
Robust product pipeline with late-stage candidates (Estelle, Donesta) in women's health.
- Specialized focus on women's health, including contraception, menopause, and hormone-dependent cancers.
- Integrated manufacturing capabilities for diverse pharmaceutical forms.
- Existing commercialized products like NEXTSTELLIS and Zoreline providing current market presence.
What Are MITPF's Weaknesses?
Significant unprofitability, indicated by a -432.1% profit margin.
- Reliance on successful clinical trial outcomes and regulatory approvals for future revenue growth.
- Operating as an OTC Other listed stock, which may imply lower liquidity and less stringent disclosure requirements.
- Limited public information on specific strategic achievements or detailed financial performance beyond core metrics.
What Could Drive MITPF Stock Higher?
MITPF catalyst: Successful completion of Phase III clinical trials for Donesta, an estetrol-based oral hormone treatment, potentially leading to regulatory submission.
- Regulatory approval and subsequent commercial launch of Estelle, a combined oral contraceptive that has completed Phase III clinical trials.
- Expansion of market penetration and sales growth for NEXTSTELLIS, an existing oral contraceptive pill in key geographic regions.
- Progress in strategic partnerships or licensing agreements for pipeline products to facilitate broader market access and commercialization.
What Are the Key Risks for MITPF?
Financial-distress signal — its Altman Z-Score of -1.48 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Failure to secure regulatory approvals for late-stage pipeline products like Estelle and Donesta, impacting future revenue generation.
- Significant unprofitability, with a profit margin of -432.1%, indicating substantial ongoing losses that could strain financial resources.
- Intense competition within the women's health pharmaceutical market from larger, more established players with greater resources.
- Risks associated with trading on the OTC Other tier, including lower liquidity, less stringent disclosure requirements, and potential difficulty in accessing capital.
- Clinical trial setbacks or unexpected adverse events for products currently in development, which could delay or halt commercialization.
What Are the Growth Opportunities for MITPF?
- Growth opportunity 1: Successful Commercialization of Estelle. Estelle, a combined oral contraceptive that has completed Phase III clinical trials, represents a significant near-term growth driver. The global oral contraceptive market is substantial, with projections indicating continued growth due to increasing demand for family planning solutions. Successful regulatory approval and subsequent commercial launch of Estelle could unlock significant revenue streams for Mithra, leveraging its differentiated estetrol component to capture market share from existing products. The timeline for this opportunity is contingent on regulatory processes and market entry strategies, likely within the next 1-3 years following approval.
- Growth opportunity 2: Advancement and Launch of Donesta. Donesta, an estetrol-based oral hormone treatment currently in Phase III development, targets the menopause management market. This market is expanding rapidly due to demographic shifts, particularly an aging global female population seeking effective and safe treatments for menopausal symptoms. Bringing Donesta to market would allow Mithra to address a large and underserved patient population, potentially establishing a strong presence in the hormone therapy segment. The successful completion of Phase III trials and subsequent regulatory approval would be critical milestones, with commercialization expected in the mid-term (3-5 years).
- Growth opportunity 3: Expansion of NEXTSTELLIS Market Penetration. NEXTSTELLIS, an existing oral contraceptive pill in Mithra's portfolio, offers an immediate opportunity for revenue growth through increased market penetration. By expanding its geographic reach, strengthening marketing efforts, and securing broader formulary access, Mithra can capitalize on the established demand for oral contraceptives. This ongoing opportunity involves strategic partnerships and commercial execution to maximize the product's sales potential in various regions, contributing to sustained revenue growth in the short to medium term.
- Growth opportunity 4: Diversification of Manufacturing Capabilities. Mithra's manufacturing capabilities, extending to polymeric products, implants, sterile injectable products, and hormonal tablets, present an opportunity to expand contract manufacturing services or develop new product lines beyond its current focus. Leveraging these diverse capabilities could allow the company to enter adjacent therapeutic areas or offer specialized manufacturing to other pharmaceutical companies, diversifying its revenue streams and reducing reliance on its proprietary drug pipeline. This long-term opportunity could involve strategic investments in capacity and technology.
- Growth opportunity 5: Development in Hormone-Dependent Cancers. The inclusion of Zoreline, a biodegradable subcutaneous implant for prostate and breast cancers, highlights Mithra's presence in the oncology market. Further research and development into new indications or improved formulations for hormone-dependent cancers could open up significant growth avenues. The oncology market is characterized by high unmet needs and premium pricing for innovative treatments. Expanding its oncology pipeline or securing additional approvals for Zoreline could provide substantial revenue growth and market differentiation in the long term (5+ years).
What Threats Does MITPF Face?
- Failure to obtain regulatory approvals for pipeline products.
- Intense competition from larger pharmaceutical companies with established women's health portfolios.
- Market acceptance and reimbursement challenges for new products.
- Potential for increased regulatory scrutiny or changes in healthcare policies affecting women's health products.
What Are MITPF's Competitive Advantages?
- Specialized focus on women's health, allowing for deep expertise and targeted product development in a specific therapeutic area.
- Proprietary pipeline of estetrol-based products, such as Estelle and Donesta, which may offer differentiated efficacy and safety profiles.
- Integrated capabilities spanning R&D, clinical development, and diverse manufacturing, providing control over the product lifecycle.
- Existing commercialized products like NEXTSTELLIS and Zoreline, which provide current revenue streams and market presence.
What Does MITPF Do?
Mithra Pharmaceuticals S.A., established in 1999 and headquartered in Liège, Belgium, operates as a pharmaceutical company dedicated to the global development, manufacturing, and marketing of advanced therapeutic solutions. The firm's strategic focus is primarily within women's health, addressing critical areas such as contraception, menopause management, and the treatment of hormone-dependent cancers. Mithra has cultivated a robust product pipeline, featuring several key assets. Among these is Estelle, a combined oral contraceptive that has successfully completed Phase III clinical trials, indicating its advanced stage of development. Another significant candidate is Donesta, an estetrol-based oral hormone treatment, which is also currently undergoing Phase III development, highlighting the company's commitment to innovation in hormonal therapies. The company's existing portfolio includes Myring, a hormone-releasing contraceptive vaginal ring, and Tibelía, a treatment specifically designed for menopause symptoms and osteoporosis. Additionally, Mithra offers Zoreline, a biodegradable subcutaneous implant with applications in prostate and breast cancers, as well as various benign gynecological indications. The company's commercialized products also include NEXTSTELLIS, an oral contraceptive pill. Beyond its specific drug formulations, Mithra Pharmaceuticals S.A. possesses comprehensive manufacturing capabilities, enabling the production of diverse pharmaceutical forms. These capabilities encompass polymeric products, implants, sterile injectable products, and various hormonal tablets, underscoring its integrated approach from research and development through to manufacturing and commercialization.
What Products and Services Does MITPF Offer?
- Develop and commercialize advanced therapeutic solutions primarily focused on women's health.
- Manufacture a range of pharmaceutical products, including polymeric products, implants, sterile injectables, and hormonal tablets.
- Conduct Phase III clinical trials for key pipeline products like Estelle (combined oral contraceptive) and Donesta (estetrol-based oral hormone treatment).
- Market and distribute existing products such as NEXTSTELLIS (oral contraceptive pill), Myring (contraceptive vaginal ring), and Tibelía (menopause/osteoporosis treatment).
- Offer Zoreline, a biodegradable implant for prostate and breast cancers, as well as benign gynecological indications.
- Focus on therapeutic areas including contraception, menopause management, and hormone-dependent cancers.
- Utilize estetrol, a naturally occurring estrogen, as a key component in several of its innovative product candidates.
How Does MITPF Make Money?
- Develops proprietary pharmaceutical products through extensive research and development, progressing them through clinical trials.
- Generates revenue from the sale and distribution of its commercialized products, such as NEXTSTELLIS, Myring, Tibelía, and Zoreline.
- Aims to license or partner its pipeline products, like Estelle and Donesta, for global commercialization, potentially earning upfront payments, milestones, and royalties.
- Leverages its manufacturing capabilities to produce diverse pharmaceutical forms, potentially offering contract manufacturing services in addition to its own products.
What Industry Does MITPF Operate In?
Mithra Pharmaceuticals S.A. operates within the dynamic and specialized 'Drug Manufacturers - Specialty & Generic' industry, specifically targeting the women's health segment of the broader healthcare sector. This segment is characterized by consistent demand for contraception, menopause management, and treatments for hormone-dependent conditions. The global women's health market continues to expand, driven by increasing awareness, an aging population, and advancements in medical science. Mithra's focus on innovative estetrol-based therapies, such as Estelle and Donesta, positions it to potentially capture market share by offering differentiated solutions. The competitive landscape includes both large multinational pharmaceutical corporations with established women's health portfolios and smaller, specialized biopharmaceutical companies. Mithra's strategy appears to be centered on leveraging its R&D pipeline to introduce novel products, thereby carving out a niche against generic competition and existing branded drugs. The success of its late-stage candidates will be crucial in solidifying its competitive standing within this growing market.
Who Are MITPF's Key Customers?
- Healthcare providers, including gynecologists, oncologists, and general practitioners, who prescribe the company's therapeutic solutions.
- Women seeking contraception, menopause management, or treatments for hormone-dependent conditions.
- Patients diagnosed with prostate or breast cancers, or various benign gynecological conditions requiring specific implantable therapies.
- Wholesalers, pharmacies, and distributors who facilitate the supply chain of pharmaceutical products to end-users.
Company Profile
Mithra Pharmaceuticals S.A. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Liège, BE. The company is led by CEO Christophe Marechal. MITPF has traded publicly since 2020.
How Mithra Pharmaceuticals S.A. Is Valued
Mithra Pharmaceuticals S.A. carries a market capitalization of $1.60B, placing it in the small-cap category. Relative to its peer group, MITPF's quantitative score of 43/100 is below the peer average of 73/100.
Key Financial Metrics
Return on equity for Mithra Pharmaceuticals S.A. stands at 498.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -60.5%, showing how much profit it generates from its asset base. Its free cash flow yield is -15.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.90 means current liabilities exceed short-term assets, a liquidity point worth watching.
Financial Health
Mithra Pharmaceuticals S.A.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -1.48 places it in the distress zone, a signal of elevated financial risk.
Forward Outlook
Wall Street analysts project Mithra Pharmaceuticals S.A. revenue of about $155.4M for fiscal 2026, with EPS near $0.62.
MITPF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Robust product pipeline with late-stage candidates (Estelle, Donesta) in women's health.
- Specialized focus on women's health, including contraception, menopause, and hormone-dependent cancers.
- Integrated manufacturing capabilities for diverse pharmaceutical forms.
- Existing commercialized products like NEXTSTELLIS and Zoreline providing current market presence.
Bear Case
- Significant unprofitability, indicated by a -432.1% profit margin.
- Reliance on successful clinical trial outcomes and regulatory approvals for future revenue growth.
- Operating as an OTC Other listed stock, which may imply lower liquidity and less stringent disclosure requirements.
- Limited public information on specific strategic achievements or detailed financial performance beyond core metrics.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
MITPF Latest News
No recent news available for MITPF.
MITPF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for MITPF.
Price Targets
Wall Street price target analysis for MITPF.
MITPF MoonshotScore
What does this score mean?
The MoonshotScore rates MITPF 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Christophe Marechal
Chief Executive Officer
Information regarding Christophe Marechal's specific career history, educational background, and previous professional roles prior to his leadership at Mithra Pharmaceuticals S.A. is not explicitly detailed within the provided source data. Therefore, a comprehensive biographical sketch outlining his credentials and professional journey cannot be constructed at this time. Further research would be required to ascertain these specific details, which are crucial for a complete understanding of his professional foundation.
Track Record: Details pertaining to Christophe Marechal's specific key achievements, strategic decisions, or company milestones directly attributable to his leadership at Mithra Pharmaceuticals S.A. are not available in the provided source materials. Consequently, a detailed track record of his impact on the company's trajectory cannot be presented based on the current information. His role involves managing 270 employees, indicating significant operational responsibilities.
MITPF OTC Market Information
Mithra Pharmaceuticals S.A. trades on the OTC market under the 'OTC Other' tier. This classification typically includes companies that do not meet the minimum financial or disclosure standards for higher OTC tiers like OTCQX or OTCQB, nor for major exchanges like the NYSE or NASDAQ. Companies in the 'OTC Other' tier often have limited public disclosure, which can make it challenging for investors to access comprehensive and timely financial information. This tier is distinct from regulated exchanges which impose strict listing requirements regarding financial health, corporate governance, and reporting frequency, aiming to protect investors through transparency and liquidity.
- OTC Tier: OTC Other
- Limited public disclosure due to 'Unknown' disclosure status, hindering informed investment decisions.
- Potentially lower liquidity and wider bid-ask spreads, leading to increased trading costs and difficulty in executing trades.
- Less stringent listing requirements compared to major exchanges, which may imply higher inherent risks regarding company stability and governance.
- Increased susceptibility to market manipulation due to lower trading volumes and less oversight.
- Difficulty in obtaining reliable and timely financial information, making fundamental analysis more challenging.
- Verify the company's most recent financial statements and annual reports, if available, from alternative sources.
- Research any news or press releases issued by the company regarding its clinical trials and regulatory progress.
- Assess the management team's experience and track record, seeking information beyond what is publicly available on OTC platforms.
- Evaluate the competitive landscape and market potential for Mithra's key products, especially Estelle and Donesta.
- Understand the regulatory environment for women's health pharmaceuticals in its target markets.
- Investigate any legal or regulatory actions against the company or its leadership.
- Analyze the company's capital structure and funding needs for its ongoing R&D and commercialization efforts.
- Headquartered in Liège, Belgium, indicating a physical operational base.
- Established in 1999, suggesting a history of operation in the pharmaceutical sector.
- Focus on specific therapeutic areas (women's health) with a defined product pipeline.
- Employs 270 individuals, indicating a substantive operational workforce.
- Publicly available information on key products like Estelle, Donesta, and NEXTSTELLIS, confirming active development and commercialization.
Common Questions About MITPF (Healthcare)
What does the AI Score mean for MITPF?
MITPF holds an AI Score of 43/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Mithra Pharmaceuticals S.A. is a Belgian pharmaceutical company specializing in women's health, developing and commercializing advanced therapeutic solutions for contraception, menopause, …
What does Mithra Pharmaceuticals S.A. do?
Mithra Pharmaceuticals S.A. is a Belgian pharmaceutical company specializing in the development, manufacturing, and marketing of advanced therapeutic solutions, primarily within the women's health sector. Its core focus areas include contraception, menopause management, and treatments for hormone-dependent cancers.
What are the key growth opportunities for MITPF in women's health?
Mithra Pharmaceuticals S.A.'s primary growth opportunities in women's health are centered on the successful commercialization of its advanced pipeline products. The anticipated regulatory approvals and market launches of Estelle (a combined oral contraceptive) and Donesta (an estetrol-based oral hormone treatment for menopause) represent significant drivers.
How does Mithra Pharmaceuticals S.A. manage its product pipeline and regulatory risks?
Mithra Pharmaceuticals S.A. manages its product pipeline by strategically focusing on late-stage clinical development, as evidenced by Estelle and Donesta both being in Phase III trials. This approach aims to bring products closer to market, reducing some early-stage development risks.
What are the main risks for MITPF, especially as an OTC-listed company?
The main risks for Mithra Pharmaceuticals S.A. include the inherent uncertainties of pharmaceutical development, such as potential failures in clinical trials or delays in regulatory approvals for its key pipeline products like Estelle and Donesta. Financially, the company faces significant unprofitability, indicated by a -432.1% profit margin, which necessitates continuous funding for R&D.
What are the key factors to evaluate for MITPF?
Mithra Pharmaceuticals S.A. (MITPF) holds an AI score of 43/100 (low). is positioned within the specialized women's health sector, focusing on high-demand areas like contraception and menopause management. Not financial advice.
How frequently does MITPF data refresh on this page?
MITPF's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven MITPF's recent stock price performance?
Mithra Pharmaceuticals S.A. (MITPF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Robust product pipeline with late-stage candidates (Estelle, Donesta) in women's health. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider MITPF overvalued or undervalued right now?
Mithra Pharmaceuticals S.A. (MITPF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited specific details on CEO's background and track record were available in the source data, leading to 'Unknown' entries for those sub-fields.
- No FMP PEER TICKERS were provided, so competitors section reflects this lack of data.
- No analyst ratings or consensus data were provided, so the corresponding FAQ was omitted as per instructions.